Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — Investor Presentation (June 2026)
7 slides from Cue Biopharma's investor presentation, June 2026
Slide 1: 401: Potential first-in-class bifunctional cytokine
Autoimmune & Inflammation 401: Potential first-in-class bifunctional cytokine ©2026 ©2025 ©2026Cue ©2024 Cue CueBiopharma Biopharma C ON FI D E NT I A L D O NO T D I ST R I B U T E
Slide 2: CUE-401: A Potential First-in-Class Bifunctional Cytokine
CUE-401: A Potential First-in-Class Bifunctional Cytokine Broad in Vivo Efficacy Across Novel bispecific fusion protein Near term value inflection with Immune-mediated Disease clear path to clinic Models • Combines affinity-attenuated IL-2 • Robust in vivo proof-of-mechanism • Manufacturing producti
Slide 3: 2025 Nobel Prize Recognized Importance in Understanding of FOXP3+ Tregs
2025 Nobel Prize Recognized Importance in Understanding of FOXP3⁺ Tregs as Central Regulators of Immune Tolerance1,2 Nature publication provides external validation of dual IL-2 and TGF-β agonism as a differentiated approach for durable immune tolerance with reduced off-target effects3 CUE-401: Bi-f
Slide 4: Dual Signaling Drives Immune Reprogramming Toward Tolerance
Dual IL-2 and TGF-β Signaling Drives Immune Reprogramming Toward Tolerance In vitro studies demonstrate FOXP3 induction and proliferation with CUE-401 dual agonism Control IL-2 alone Fc-TGF-β alone CUE-401 iTreg differentiation FOXP3 37 nM CFSE Source: Sponsored Research Collaboration with Dr. Richa
Slide 5: IL-2 and TGF-β Agonism Demonstrates Activity Across Inflammatory Diseases
IL-2 and TGF-β Agonism Demonstrates Activity Across Inflammatory Diseases, Supporting a Platform for Immune Tolerance Suppresses pro-inflammatory Broad in vivo efficacy across immune-mediated disease models cytokine signaling Prevention of Attenuation of Disease GVHD: Delayed Development Suppresses
Slide 6: Phase 1 Single and Multiple Ascending Dose Study in Healthy Volunteers
Phase 1 Single and Multiple Ascending Dose Study In Healthy Volunteers with Patient Cohort Expansion Single Ascending Dose 1 Placebo controlled 4 sequential dose levels Multiple Ascending Dose 1 Placebo controlled 3 dose levels plus patient Dotted arrows indicateexpansion overlap; MADcohort dosing b
Slide 7: CUE is Advancing a Portfolio of Potentially Transformative Therapies
CUE is Advancing a Portfolio of Potentially Transformative Therapies Aimed at Enabling Functional Cures Across Immunological Disorders • CUE-221: a novel anti-IgE program with a unique dual-mechanism of action in Enhanced Phase 2 for allergic disease augmenting the portfolio that includes CUE -401 c